Caveolin-1: A tumor-promoting role in human cancer

References

• Ahn M, Kim H, Kim J T, Lee J, Hyun J W, Park J W, Shin T. Gamma-ray irradiation stimulates the expression of caveolin-1 and GFAP in rat spinal cord: A study of immunoblot and immunohistochemistry. The Journal of Veterinary Science 2006; 7(4)309–314
   PubMedGoogle Scholar
• Ando T, Ishiguro H, Kimura M, Mitsui A, Mori Y, Sugito N, Tomoda K, Mori R, Harada K, Katada T, Ogawa R, Fujii Y, Kuwabara Y. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncology Reports 2007; 18(3)601–609
   PubMedGoogle Scholar
• Annabi B, Lee Y T, Martel C, Pilorget A, Bahary J P, Beliveau R. Radiation induced-tubulogenesis in endothelial cells is antagonized by the antiangiogenic properties of green tea polyphenol (−) epigallocatechin-3-gallate. Cancer Biology and Therapy 2003; 2(6)642–649
   PubMed Web of Science ®Google Scholar
• Aoki T, Nomura R, Fujimoto T. Tyrosine phosphorylation of caveolin-1 in the endothelium. Experimental Cell Research 1999; 253(2)629–636
   PubMed Web of Science ®Google Scholar
• Ayala G E, Dai H, Tahir S A, Li R, Timme T, Ittmann M, Frolov A, Wheeler T M, Rowley D, Thompson T C. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Research 2006; 66(10)5159–5164
   PubMed Web of Science ®Google Scholar
• Barresi V, Cerasoli S, Paioli G, Vitarelli E, Giuffre G, Guiducci G, Tuccari G, Barresi G. Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuropathologica (Berl) 2006; 112(5)617–626
   PubMedGoogle Scholar
• Belanger M M, Roussel E, Couet J. Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs 2003; 14(4)281–287
   PubMedGoogle Scholar
• Bucci M, Gratton J P, Rudic R D, Acevedo L, Roviezzo F, Cirino G, Sessa W C. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nature Medicine 2000; 6(12)1362–1367
   PubMed Web of Science ®Google Scholar
• Burgermeister E, Xing X, Rocken C, Juhasz M, Chen J, Hiber M, Mair K, Shatz M, Liscovitch M, Schmid R M, Ebert M P. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Research 2007; 67(18)8519–8526
   PubMedGoogle Scholar
• Campbell L, Gumbleton M, Griffiths D F. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. British Journal of Cancer 2003; 89(10)1909–1913
   PubMedGoogle Scholar
• Capozza F, Williams T M, Schubert W, McClain S, Bouzahzah B, Sotgia F, Lisanti M P. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. American Journal of Pathology 2003; 162(6)2029–2039
   PubMedGoogle Scholar
• Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane B F. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. Journal of Cell Science 2005; 118(Pt 7)1493–1503
   PubMed Web of Science ®Google Scholar
• Cho K A, Ryu S J, Park J S, Jang I S, Ahn J S, Kim K T, Park S C. Senescent phenotype can be reversed by reduction of caveolin status. Journal of Biological Chemistry 2003; 278(30)27789–27795
   PubMedGoogle Scholar
• Cordes N, Frick S, Brunner T B, Pilarsky C, Grutzmann R, Sipos B, Kloppel G, McKenna W G, Bernhard E J. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 2007; 26(48)6851–6862
   PubMed Web of Science ®Google Scholar
• Dasari A, Bartholomew J N, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Research 2006; 66(22)10805–10814
   PubMedGoogle Scholar
• Davidson B, Nesland J M, Goldberg I, Kopolovic J, Gotlieb W H, Bryne M, Ben-Baruch G, Berner A, Reich R. Caveolin-1 expression in advanced-stage ovarian carcinoma – a clinicopathologic study. Gynecologic Oncology 2001; 81(2)166–171
   PubMedGoogle Scholar
• Dietzen D J, Hastings W R, Lublin D M. Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of caveolin to caveolae. Journal of Biological Chemistry 1995; 270(12)6838–6842
   PubMed Web of Science ®Google Scholar
• Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft F C, Schedl A, Haller H, Kurzchalia T V. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293(5539)2449–2452
   PubMed Web of Science ®Google Scholar
• Engelman J A, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz D S, Lisanti M P. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Letters 1998a; 428(3)205–211
   PubMed Web of Science ®Google Scholar
• Engelman J A, Lee R J, Karnezis A, Bearss D J, Webster M, Siegel P, Muller W J, Windle J J, Pestell R G, Lisanti M P. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. Journal of Biological Chemistry 1998b; 273(32)20448–20455
   PubMedGoogle Scholar
• Engelman J A, Zhang X L, Lisanti M P. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Letters 1998c; 436(3)403–410
   PubMedGoogle Scholar
• Fernandez M A, Albor C, Ingelmo-Torres M, Nixon S J, Ferguson C, Kurzchalia T, Tebar F, Enrich C, Parton R G, Pol A. Caveolin-1 is essential for liver regeneration. Science 2006; 313(5793)1628–1632
   PubMedGoogle Scholar
• Fielding C J, Fielding P E. Caveolae and intracellular trafficking of cholesterol. Advanced Drug Delivery Reviews 2001; 49(3)251–264
   PubMedGoogle Scholar
• Fine S W, Lisanti M P, Galbiati F, Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. American Journal Clinical of Pathology 2001; 115(5)719–724
   PubMedGoogle Scholar
• Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002; 21(15)2365–2375
   PubMedGoogle Scholar
• Fong A, Garcia E, Gwynn L, Lisanti M P, Fazzari M J, Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. American Journal Clinical of Pathology 2003; 120(1)93–100
   PubMedGoogle Scholar
• Galbiati F, Volonte D, Brown A M, Weinstein D E, Ben-Ze'ev A, Pestell R G, Lisanti M P. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. Journal of Biological Chemistry 2000; 275(30)23368–23377
   PubMedGoogle Scholar
• Galbiati F, Volonte D, Engelman J A, Watanabe G, Burk R, Pestell R G, Lisanti M P. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO Journal 1998; 17(22)6633–6648
   PubMed Web of Science ®Google Scholar
• Galbiati F, Volonte D, Liu J, Capozza F, Frank P G, Zhu L, Pestell R G, Lisanti M P. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Molecular Biology of the Cell 2001; 12(8)2229–2244
   PubMedGoogle Scholar
• Garcia-Cardena G, Martasek P, Masters B S, Skidd P M, Couet J, Li S, Lisanti M P, Sessa W C. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. Journal of Biological Chemistry 1997; 272(41)25437–25440
   PubMed Web of Science ®Google Scholar
• Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, Hamaguchi M. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Research 2001; 61(6)2361–2364
   PubMedGoogle Scholar
• Ho C C, Huang P H, Huang H Y, Chen Y H, Yang P C, Hsu S M. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. American Journal of Pathology 2002; 161(5)1647–1656
   PubMedGoogle Scholar
• Horiguchi A, Asano T, Asakuma J, Sumitomo M, Hayakawa M. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. Journal of Urology 2004; 172(2)718–722
   PubMedGoogle Scholar
• Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage D R, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti M P, Pestell R G. The cyclin D1 gene is transcriptionally repressed by caveolin-1. Journal of Biological Chemistry 2000; 275(28)21203–21209
   PubMedGoogle Scholar
• Hung K F, Lin S C, Liu C J, Chang C S, Chang K W, Kao S Y. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. Journal of Oral Pathology and Medicine 2003; 32(8)461–467
   PubMedGoogle Scholar
• Hurlstone A F, Reid G, Reeves J R, Fraser J, Strathdee G, Rahilly M, Parkinson E K, Black D M. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 1999; 18(10)1881–1890
   PubMedGoogle Scholar
• Jodoin J, Demeule M, Fenart L, Cecchelli R, Farmer S, Linton K J, Higgins C F, Beliveau R. P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. Journal of Neurochemistry 2003; 87(4)1010–1023
   PubMedGoogle Scholar
• Joo H J, Oh D K, Kim Y S, Lee K B, Kim S J. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU International 2004; 93(3)291–296
   PubMedGoogle Scholar
• Ju H, Zou R, Venema V J, Venema R C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. Journal of Biological Chemistry 1997; 272(30)18522–18525
   PubMed Web of Science ®Google Scholar
• Karam J A, Lotan Y, Roehrborn C G, Ashfaq R, Karakiewicz P I, Shariat S F. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007; 67(6)614–622
   PubMed Web of Science ®Google Scholar
• Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002; 94(4)929–933
   PubMedGoogle Scholar
• Kato T, Miyamoto M, Kato K, Cho Y, Itoh T, Morikawa T, Okushiba S, Kondo S, Ohbuchi T, Katoh H. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Letters 2004; 214(1)121–128
   PubMedGoogle Scholar
• Kimura A, Mora S, Shigematsu S, Pessin J E, Saltiel A R. The insulin receptor catalyzes the tyrosine phosphorylation of caveolin-1. Journal of Biological Chemistry 2002; 277(33)30153–30158
   PubMedGoogle Scholar
• Kunze E, Von Bonin F, Werner C, Wendt M, Schlott T. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. International Journal of Molecular Medicine 2006; 17(1)3–13
   PubMedGoogle Scholar
• Lavie Y, Cao H, Bursten S L, Giuliano A E, Cabot M C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. Journal of Biological Chemistry 1996; 271(32)19530–19536
   PubMedGoogle Scholar
• Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. Journal of Biological Chemistry 1998; 273(49)32380–32383
   PubMedGoogle Scholar
• Lavie Y, Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconjugate Journal 2000; 17(3 – 4)253–259
   PubMedGoogle Scholar
• Lee H, Park D S, Razani B, Russell R G, Pestell R G, Lisanti M P. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (−/−) null mice show mammary epithelial cell hyperplasia. American Journal of Pathology 2002; 161(4)1357–1369
   PubMedGoogle Scholar
• Lee H, Volonte D, Galbiati F, Iyengar P, Lublin D M, Bregman D B, Wilson M T, Campos-Gonzalez R, Bouzahzah B, Pestell R G, Scherer P E, Lisanti M P. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Molecular Endocrinology 2000; 14(11)1750–1775
   PubMedGoogle Scholar
• Li J, Hassan G S, Williams T M, Minetti C, Pestell R G, Tanowitz H B, Frank P G, Sotgia F, Lisanti M P. Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. Cell Cycle 2005; 4(12)1817–1825
   PubMed Web of Science ®Google Scholar
• Li L, Ren C H, Tahir S A, Ren C, Thompson T C. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Molecular Cell Biology 2003; 23(24)9389–9404
   PubMedGoogle Scholar
• Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme T L, Ren C, Wang J, Tahir S A, Thompson T C. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Research 2001a; 61(11)4386–4392
   PubMedGoogle Scholar
• Li S, Seitz R, Lisanti M P. Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. Journal of Biological Chemistry 1996; 271(7)3863–3868
   PubMedGoogle Scholar
• Li T, Sotgia F, Vuolo M A, Li M, Yang W C, Pestell R G, Sparano J A, Lisanti M P. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. American Journal of Pathology 2006; 168(6)1998–2013
   PubMed Web of Science ®Google Scholar
• Li W P, Liu P, Pilcher B K, Anderson R G. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. Journal of Cell Science 2001b; 114(Pt 7)1397–1408
   PubMed Web of Science ®Google Scholar
• Lisanti M P, Scherer P E, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu Y H, Cook R F, Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. Journal of Cell Biology 1994; 126(1)111–126
   PubMedGoogle Scholar
• Liscovitch M, Burgermeister E, Jain N, Ravid D, Shatz M, Tencer L. Caveolin and cancer: A complex relationship. Membrane microdomain signaling: Lipid rafts in biology and medicine, M P Mattson. Humana Press, Totowa, New Jersey 2005; 161–190
   Google Scholar
• Liu P, Li W P, Machleidt T, Anderson R G. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nature Cell Biology 1999; 1(6)369–375
   PubMed Web of Science ®Google Scholar
• Liu P, Rudick M, Anderson R G. Multiple functions of caveolin-1. Journal of Biological Chemistry 2002; 277(44)41295–41298
   PubMed Web of Science ®Google Scholar
• Loza-Coll M A, Perera S, Shi W, Filmus J. A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells. Oncogene 2005; 24(10)1727–1737
   PubMedGoogle Scholar
• Maggi D, Biedi C, Segat D, Barbero D, Panetta D, Cordera R. IGF-I induces caveolin 1 tyrosine phosphorylation and translocation in the lipid rafts. Biochemical and Biophysical Research Communications 2002; 295(5)1085–1089
   PubMedGoogle Scholar
• McLaughlin N, Annabi B, Bouzeghrane M, Temme A, Bahary J P, Moumdjian R, Beliveau R. The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (−)-epigallocatechin-3-gallate. Brain Research 2006; 1071(1)1–9
   PubMedGoogle Scholar
• Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick J K, Giancotti F G. Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. Molecular Cell 2001; 8(1)115–127
   PubMedGoogle Scholar
• Montesano R, Roth J, Robert A, Orci L. Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature 1982; 296(5858)651–653
   PubMedGoogle Scholar
• Moon K C, Lee G K, Yoo S H, Jeon Y K, Chung J H, Han J, Chung D H. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Research 2005; 25(6C)4631–4637
   PubMedGoogle Scholar
• Nabi I R, Le P U. Caveolae/raft-dependent endocytosis. Journal of Cell Biology 2003; 161(4)673–677
   PubMed Web of Science ®Google Scholar
• Nasu Y, Timme T L, Yang G, Bangma C H, Li L, Ren C, Park S H, DeLeon M, Wang J, Thompson T C. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nature Medicine 1998; 4(9)1062–1064
   PubMedGoogle Scholar
• Pang A, Au W Y, Kwong Y L. Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leukemia Research 2004; 28(9)973–977
   PubMedGoogle Scholar
• Park D S, Lee H, Frank P G, Razani B, Nguyen A V, Parlow A F, Russell R G, Hulit J, Pestell R G, Lisanti M P. Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Molecular Biology of the Cell 2002; 13(10)3416–3430
   PubMedGoogle Scholar
• Rajjayabun P H, Garg S, Durkan G C, Charlton R, Robinson M C, Mellon J K. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001; 58(5)811–814
   PubMedGoogle Scholar
• Ravid D, Maor S, Werner H, Liscovitch M. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 2005; 24(8)1338–1347
   PubMedGoogle Scholar
• Razani B, Engelman J A, Wang X B, Schubert W, Zhang X L, Marks C B, Macaluso F, Russell R G, Li M, Pestell R G, Di Vizio D, Hou H, Jr, Kneitz B, Lagaud G, Christ G J, Edelmann W, Lisanti M P. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. Journal of Biological Chemistry 2001a; 276(41)38121–38138
   PubMed Web of Science ®Google Scholar
• Razani B, Schlegel A, Liu J, Lisanti M P. Caveolin-1, a putative tumour suppressor gene. Biochemical Society Transactions 2001b; 29(Pt 4)494–499
   PubMedGoogle Scholar
• Razani B, Woodman S E, Lisanti M P. Caveolae: From cell biology to animal physiology. Pharmacological Reviews 2002; 54(3)431–467
   PubMedGoogle Scholar
• Regina A, Jodoin J, Khoueir P, Rolland Y, Berthelet F, Moumdjian R, Fenart L, Cecchelli R, Demeule M, Beliveau R. Down-regulation of caveolin-1 in glioma vasculature: modulation by radiotherapy. Journal of Neuroscience Research 2004; 75(2)291–299
   PubMedGoogle Scholar
• Ronaldson P T, Bendayan M, Gingras D, Piquette-Miller M, Bendayan R. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. Journal of Neurochemistry 2004; 89(3)788–800
   PubMed Web of Science ®Google Scholar
• Roussel E, Belanger M M, Couet J. G2/M blockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells: Caveolin-1 as a marker of cytotoxicity. Anticancer Drugs 2004; 15(10)961–967
   PubMedGoogle Scholar
• Ryu S J, Cho K A, Oh Y S, Park S C. Role of Src-specific phosphorylation site on focal adhesion kinase for senescence-associated apoptosis resistance. Apoptosis 2006; 11(3)303–313
   PubMedGoogle Scholar
• Salatino M, Beguelin W, Peters M G, Carnevale R, Proietti C J, Galigniana M D, Vedoy C G, Schillaci R, Charreau E H, Sogayar M C, Elizalde P V. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene 2006; 25(59)7723–7739
   PubMedGoogle Scholar
• Sallinen S L, Sallinen P K, Haapasalo H K, Helin H J, Helen P T, Schraml P, Kallioniemi O P, Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Research 2000; 60(23)6617–6622
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Socci N D, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C. Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes. Cancer Research 2002; 62(23)6973–6980
   PubMed Web of Science ®Google Scholar
• Sato Y, Sagami I, Shimizu T. Identification of caveolin-1-interacting sites in neuronal nitric-oxide synthase. Molecular mechanism for inhibition of NO formation. Journal of Biological Chemistry 2004; 279(10)8827–8836
   PubMed Web of Science ®Google Scholar
• Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme T L, Baba S, Thompson T C. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 2003; 97(5)1225–1233
   PubMed Web of Science ®Google Scholar
• Savage K, Lambros M B, Robertson D, Jones R L, Jones C, Mackay A, James M, Hornick J L, Pereira E M, Milanezi F, Fletcher C D, Schmitt F C, Ashworth A, Reis-Filho J S. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clinical Cancer Research 2007; 13(1)90–101
   PubMedGoogle Scholar
• Scherer P E, Tang Z, Chun M, Sargiacomo M, Lodish H F, Lisanti M P. Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe. Journal of Biological Chemistry 1995; 270(27)16395–16401
   PubMed Web of Science ®Google Scholar
• Schlegel A, Arvan P, Lisanti M P. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. Journal of Biological Chemistry 2001; 276(6)4398–4408
   PubMedGoogle Scholar
• Schlegel A, Lisanti M P. A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo. Journal of Biological Chemistry 2000; 275(28)21605–21617
   PubMedGoogle Scholar
• Sedding D G, Hermsen J, Seay U, Eickelberg O, Kummer W, Schwencke C, Strasser R H, Tillmanns H, Braun-Dullaeus R C. Caveolin-1 facilitates mechanosensitive protein kinase B (Akt) signaling in vitro and in vivo. Circulation Research 2005; 96(6)635–642
   PubMedGoogle Scholar
• Shack S, Wang X T, Kokkonen G C, Gorospe M, Longo D L, Holbrook N J. Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Molecular Cell Biology 2003; 23(7)2407–2414
   PubMedGoogle Scholar
• Siddiqui S S, Siddiqui Z K, Uddin S, Minshall R D, Malik A B. p38 MAPK activation coupled to endocytosis is a determinant of endothelial monolayer integrity. American Journal of Physiology Lung Cellular and Molecular Physiology 2007; 292(1)L114–124
   Google Scholar
• Sotgia F, Schubert W, Pestell R G, Lisanti M P. Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biology and Therapy 2006; 5(3)292–297
   PubMed Web of Science ®Google Scholar
• Sowa G, Pypaert M, Sessa W C. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proceedings of the National Academy of Sciences USA 2001; 98(24)14072–14077
   PubMedGoogle Scholar
• Sunaga N, Miyajima K, Suzuki M, Sato M, White M A, Ramirez R D, Shay J W, Gazdar A F, Minna J D. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Research 2004; 64(12)4277–4285
   PubMedGoogle Scholar
• Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, Katoh H. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. British Journal of Cancer 2002; 87(10)1140–1144
   PubMedGoogle Scholar
• Szakacs G, Paterson J K, Ludwig J A, Booth-Genthe C, Gottesman M M. Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 2006; 5(3)219–234
   PubMed Web of Science ®Google Scholar
• Tahir S A, Frolov A, Hayes T G, Mims M P, Miles B J, Lerner S P, Wheeler T M, Ayala G, Thompson T C, Kadmon D. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clinical Cancer Research 2006; 12(16)4872–4875
   PubMed Web of Science ®Google Scholar
• Tahir S A, Yang G, Ebara S, Timme T L, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett J D, Thompson T C. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Research 2001; 61(10)3882–3885
   PubMed Web of Science ®Google Scholar
• Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine N R. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. American Journal of Pathology 2002; 160(5)1745–1754
   PubMedGoogle Scholar
• Timme T L, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston R N, Thompson T C. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000; 19(29)3256–3265
   PubMedGoogle Scholar
• Tirado O M, Mateo-Lozano S, Villar J, Dettin L E, Llort A, Gallego S, Ban J, Kovar H, Notario V. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Research 2006; 66(20)9937–9947
   PubMed Web of Science ®Google Scholar
• Uittenbogaard A, Ying Y, Smart E J. Characterization of a cytosolic heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. Journal of Biological Chemistry 1998; 273(11)6525–6532
   PubMedGoogle Scholar
• Van den Eynden G G, Van Laere S J, Van der Auwera I, Merajver S D, Van Marck E A, van Dam P, Vermeulen P B, Dirix L Y, van Golen K L. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Research and Treatment 2006; 95(3)219–228
   PubMed Web of Science ®Google Scholar
• Volonte D, Zhang K, Lisanti M P, Galbiati F. Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Molecular Biology of the Cell 2002; 13(7)2502–2517
   PubMed Web of Science ®Google Scholar
• Wary K K, Mariotti A, Zurzolo C, Giancotti F G. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 1998; 94(5)625–634
   PubMedGoogle Scholar
• Williams T M, Cheung M W, Park D S, Razani B, Cohen A W, Muller W J, Di Vizio D, Chopra N G, Pestell R G, Lisanti M P. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Molecular Biology of the Cell 2003; 14(3)1027–1042
   PubMedGoogle Scholar
• Williams T M, Hassan G S, Li J, Cohen A W, Medina F, Frank P G, Pestell R G, Di Vizio D, Loda M, Lisanti M P. Caveolin-1 Promotes Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. Journal of Biological Chemistry 2005; 280(26)25134–25145
   PubMed Web of Science ®Google Scholar
• Williams T M, Lisanti M P. Caveolin-1 in oncogenic transformation, cancer, and metastasis. American Journal of Physiology Cell Physiology 2005; 288(3)C494–506
   Google Scholar
• Wu D, Foreman T L, Gregory C W, McJilton M A, Wescott G G, Ford O H, Alvey R F, Mohler J L, Terrian D M. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Research 2002; 62(8)2423–2429
   PubMedGoogle Scholar
• Xie Z, Zeng X, Waldman T, Glazer R I. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Research 2003; 63(17)5370–5375
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Komekado H, Kikuchi A. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Developmental Cell 2006; 11(2)213–223
   PubMedGoogle Scholar
• Yang C P, Galbiati F, Volonte D, Horwitz S B, Lisanti M P. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Letters 1998a; 439(3)368–372
   PubMedGoogle Scholar
• Yang G, Addai J, Ittmann M, Wheeler T M, Thompson T C. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clinical Cancer Research 2000; 6(9)3430–3433
   PubMedGoogle Scholar
• Yang G, Timme T L, Frolov A, Wheeler T M, Thompson T C. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 2005; 103(6)1186–1194
   PubMedGoogle Scholar
• Yang G, Truong L D, Timme T L, Ren C, Wheeler T M, Park S H, Nasu Y, Bangma C H, Kattan M W, Scardino P T, Thompson T C. Elevated expression of caveolin is associated with prostate and breast cancer. Clinical Cancer Research 1998b; 4(8)1873–1880
   PubMedGoogle Scholar
• Yang G, Truong L D, Wheeler T M, Thompson T C. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Research 1999; 59(22)5719–5723
   PubMed Web of Science ®Google Scholar
• Yoo S H, Park Y S, Kim H R, Sung S W, Kim J H, Shim Y S, Lee S D, Choi Y L, Kim M K, Chung D H. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003; 42(2)195–202
   PubMedGoogle Scholar
• Zuluaga S, Alvarez-Barrientos A, Gutierrez-Uzquiza A, Benito M, Nebreda A R, Porras A. Negative regulation of Akt activity by p38alpha MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1. Cell Signaling 2007; 19(1)62–74
   PubMedGoogle Scholar
• Zundel W, Swiersz L M, Giaccia A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Molecular Cell Biology 2000; 20(5)1507–1514
   PubMedGoogle Scholar